Collectively, these results demonstrate that LINC00052 promotes cancer cell growth and survival by upregulating HER3, and that high LINC00052 levels predict an increased sensitivity of breast cancer cells to HER3 neutralizing antibody treatment. Here, ERBB3 is linked to cancer.